GR
$127.06
-5.54
(-4.18%)
As of Oct 22, 2026, 9:32 PM EDT · cached
Price history
Grail Inc (GRAL) is trading down at $127.06 (-4.18%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Grail Inc revenue & net income history (FY2022–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2022Jan 2023 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $55.5M | $93.1M | $125.6M | $147.2M |
| Growth (year over year) | — | +67.6% | +34.9% | +17.2% |
| Operating income | −$5.44B | −$1.52B | −$2.19B | −$562.2M |
| Operating margin | −9798.2% | −1627.6% | −1743.0% | −382.0% |
| Net income | −$5.40B | −$1.47B | −$2.03B | −$408.4M |
| Net margin | −9719.3% | −1574.2% | −1613.9% | −277.5% |
| EPS (diluted) | −$173.89 | −$47.21 | −$63.54 | −$11.11 |
| Balance sheet | ||||
| Cash and equivalents | $241.6M | $97.3M | $214.2M | $249.7M |
| Total assets | — | $3.91B | $2.98B | $2.92B |
| Total liabilities | — | $267.6M | $479.9M | $344.2M |
| Shareholders' equity | — | — | $2.50B | $2.58B |
| Cash flow | ||||
| Operating cash flow | −$561.3M | −$595.8M | −$577.2M | −$299.0M |
| Capital expenditure | $22.9M | $12.9M | $5.21M | $909.0K |
| Free cash flow | −$584.2M | −$608.7M | −$582.4M | −$299.9M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $28.7M | $38.3M | $31.8M | $35.5M | $36.2M | $43.6M | $40.8M | $44.7M |
| Growth (year over year) | +38.3% | +26.1% | +19.1% | +11.2% | +26.3% | +14.0% | +28.1% | +25.7% |
| Operating income | −$183.5M | −$136.9M | −$153.6M | −$158.9M | −$125.3M | −$124.4M | −$135.8M | −$173.8M |
| Operating margin | −640.5% | −358.0% | −482.5% | −446.9% | −346.2% | −285.4% | −332.9% | −388.9% |
| Net income | −$125.7M | −$97.1M | −$106.2M | −$114.0M | −$89.0M | −$99.2M | −$93.2M | −$110.2M |
| Net margin | −438.7% | −253.8% | −333.6% | −320.7% | −245.8% | −227.5% | −228.5% | −246.7% |
| EPS (diluted) | −$3.94 | −$1.49 | −$3.10 | −$3.18 | −$2.46 | −$2.37 | −$2.29 | −$2.56 |
| Balance sheet | ||||||||
| Cash and equivalents | $853.6M | $214.2M | $133.9M | $127.4M | $126.9M | $249.7M | $69.3M | $55.6M |
| Total assets | $3.12B | $2.98B | $2.85B | $2.70B | $2.60B | $2.92B | $2.80B | $2.84B |
| Total liabilities | $530.3M | $479.9M | $433.9M | $387.9M | $361.1M | $344.2M | $302.8M | $301.0M |
| Shareholders' equity | $2.59B | $2.50B | $2.41B | $2.31B | $2.24B | $2.58B | $2.50B | $2.54B |
| Cash flow | ||||||||
| Operating cash flow | −$104.6M | −$93.5M | −$95.0M | −$77.0M | −$63.2M | −$63.8M | −$87.0M | −$80.7M |
| Capital expenditure | $971.0K | $303.0K | $62.0K | $369.0K | $384.0K | $94.0K | $503.0K | $432.0K |
| Free cash flow | −$105.6M | −$93.8M | −$95.1M | −$77.3M | −$63.6M | −$63.9M | −$87.5M | −$81.2M |
From Grail Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Grail Inc
- Headquarters
- Sunnyvale, California From SEC filings, Oct 2026
Recent News (8)
-
GRAIL to Announce Third Quarter 2026 Financial Results SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue finan…
-
Grail CEO Joshua Ofman sells $2.74m in company stock
Grail CEO Joshua Ofman sells $2.74m in company stock
-
Nvidia's next 'holy grail' is physical AI: Dan Ives Nvidia's next 'holy grail' is physical AI: Dan Ives Yahoo Finance
-
Dow Jones Futures Fall As Treasury Yields, Oil Prices Keep Rising. Meta, Everpure, Grail Are Early Movers. Dow Jones Futures Fall As Treasury Yields, Oil Prices Keep Rising. Meta, Everpure, Grail Are Early Movers. Investor's Business Daily
-
AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s Market
AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s Market
-
AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s Market AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s Market Barron's
-
GRAIL at Morgan Stanley conference: FDA, coverage seen as key
GRAIL at Morgan Stanley conference: FDA, coverage seen as key
-
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International